Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 May 12;3:13. doi: 10.1038/s41392-018-0013-x

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2018

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 2 — MUC1-C drives BCL2A1 expression. a Schema of the MUC1-C subunit with the sequence of the 72-amino acid intrinsically disordered cytoplasmic domain (CD). The CQC motif is required for MUC1-C homodimerization and is the target of GO-203. The MUC1-C cytoplasmic domain activates the inflammatory TAK1→IKK→NF-κB p65 pathway by direct interactions with these effectors. b, c MDA-MB-468 (b) and BT-20 (c) cells stably transduced to express a control or MUC1-C vector were analyzed for BCL2A1 mRNA levels by qRT–PCR. The results (mean ± SD of 3 determinations) are expressed as BCL2A1 mRNA levels relative to those in vector cells (assigned a value of 1) (left). Lysates were immunoblotted with the indicated antibodies (right). d, e MDA-MB-468 (d) and BT-20 (e) cells treated with empty NPs or 7.5 μM GO-203/NPs for 5 d were analyzed for BCL2A1 mRNA levels by qRT–PCR. The results (mean ± SD of three determinations) are expressed as BCL2A1 mRNA levels relative to those in cells treated with empty NPs (assigned a value of 1) (left). Lysates from cells treated with empty NPs or 7.5 μM GO-203/NPs for 7 d were immunoblotted with the indicated antibodies (right)